Suppr超能文献

经动脉化疗栓塞术后血清甲胎蛋白轨迹与中期肝细胞癌预后:一项纵向、回顾性、多中心队列研究

Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study.

作者信息

Lu Linbin, Shen Lujun, Wu Zhixian, Shi Yanhong, Hou Peifeng, Xue Zengfu, Lin Cheng, Chen Xiong

机构信息

Department of Oncology, The 900th Hospital of Joint Logistic Support Force, PLA, Fuzong Clinical College of Fujian Medical University, 156 Xierhuan Northern Road, Fuzhou, Fujian 350025, PR China.

Department of Minimally Invasive Interventional Therapy, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, PR China.

出版信息

EClinicalMedicine. 2022 Apr 16;47:101391. doi: 10.1016/j.eclinm.2022.101391. eCollection 2022 May.

Abstract

BACKGROUND

α-fetoprotein (AFP) response has been proven a key tumor marker for hepatocellular carcinoma (HCC), but its definition remains controversial. This study aims to characterize AFP trajectories after transarterial chemoembolization (TACE) and examine its impact on clinical outcomes.

METHODS

This longitudinal, multicenter, retrospective, cohort study examined data from the electronic medical record system of four hospitals in China between January 1, 2007 to December 31, 2016. A latent class growth mixed model was applied to distinguish potential AFP dynamic changing trajectories. The multivariable Cox models were used to calculate adjusted hazard ratios (aHRs) and 95% CIs for overall survival. Inverse-probability-of-treatment weighted analyses were performed to eliminate unmeasured confounders through marginal structural models.

FINDINGS

A total of 881 patients, who had intermediate-stage HCC with AFP repeatedly measured 3 to 10 times, were included in the study. Three distinct trajectories were identified using the latent class growth mixture model: high-rising (25.7%;  = 226), low-stable (58.7%;  = 517), and sharp-falling (AFP serological response, 15.6%;  = 138). Compared with the low-stable class, the aHRs for death were 5.13 (3.71, 7.10) and 0.52 (0.33, 0.81) for the high-rising and sharp-falling class, adjusted by gender, baseline major tumor size, intrahepatic lesions number, and logAFP(smooth). Furthermore, high-rising class had a significantly higher HR in the subgroup of female patients (10.60, 95%CI: 6.29, 17.86), age<55 (6.78, 95%CI: 4.79, 9.59) and Child-Pugh class B (23.01, 95%CI:8.07, 65.63) ( = 0.014, 0.046 and 0.033 for interaction, respectively). Trajectories of AFP had the highest relative importance of each parameter to survival, including largest tumor size, intrahepatic lesions number, Child-Pugh class, and baseline AFP.

INTERPRETATION

AFP trajectories were associated with overall survival for intermediate-stage HCC after TACE.

FUNDING

The Natural Science Foundation of Fujian Province (Nos. 2018J01352, 2016J01576 and 2016J01586); the Science and Technology Innovation Joint Foundation of Fujian Province (Nos. 2017Y9125).

摘要

背景

甲胎蛋白(AFP)反应已被证明是肝细胞癌(HCC)的关键肿瘤标志物,但其定义仍存在争议。本研究旨在描述经动脉化疗栓塞术(TACE)后AFP的变化轨迹,并探讨其对临床结局的影响。

方法

本纵向、多中心、回顾性队列研究分析了2007年1月1日至2016年12月31日期间中国四家医院电子病历系统中的数据。采用潜在类别增长混合模型来区分潜在的AFP动态变化轨迹。多变量Cox模型用于计算总生存的调整风险比(aHRs)和95%可信区间(CIs)。通过逆概率加权分析,利用边际结构模型消除未测量的混杂因素。

结果

共有881例中期HCC患者纳入研究,这些患者的AFP被重复测量3至10次。使用潜在类别增长混合模型确定了三种不同的轨迹:高上升型(25.7%;n = 226)、低稳定型(58.7%;n = 517)和急剧下降型(AFP血清学反应,15.6%;n = 138)。与低稳定型相比,经性别、基线主要肿瘤大小、肝内病变数量和logAFP(平滑值)调整后,高上升型和急剧下降型的死亡aHRs分别为5.13(3.71,7.10)和0.52(0.33,0.81)。此外,在女性患者亚组(10.60,95%CI:6.29,17.86)、年龄<55岁(6.78,95%CI:4.79,9.59)和Child-Pugh B级(23.01,95%CI:8.07,65.63)患者中,高上升型具有显著更高的HR(交互作用P值分别为0.014、0.046和0.033)。AFP轨迹对生存的相对重要性在各参数中最高,包括最大肿瘤大小、肝内病变数量、Child-Pugh分级和基线AFP。

解读

TACE术后,中期HCC患者的AFP轨迹与总生存相关。

资助

福建省自然科学基金(编号2018J01352、2016J01576和2016J01586);福建省科技创新联合基金(编号2017Y9125)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5817/9035711/bcbf228551b0/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验